Company intelligence / Profile preview

Melinta Therapeutics

Parsippany, New Jersey, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Employees: ~150
Development stage: Commercial

Overview

Melinta has multiple FDA-approved antibiotics for serious hospital-based infections. Its recent antifungal REZZAYO® was approved in the U.S. in early 2023. The company continues to expand its portfolio through licensing agreements such as cefepime-taniborbactam with Venatorx Pharmaceuticals.

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (antibiotics/antibacterials)Antifungals
Industry: Biotech

Drug pipeline

6 assets

delafloxacin

Approved

5 more assets in the full pipeline.

Request access →

Partnerships

Venatorx Pharmaceuticals – U.S. commercialization of cefepime-taniborbactamFormer collaboration with Sanofi on novel antibiotics research/licensing option agreement

Beyond the preview

Go deeper on Melinta Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Melinta Therapeutics.

Explore the full profile